| [1] |
Salmaninejad A, Zamani MR, Shabgah AG, et al. Behçet's disease: An immunogenetic perspective[J]. Cell Physiol, 2019, 234(6): 8055-8074.
|
| [2] |
Davatchi F, Chams-Davatchi C, Shams H, et al. Behcet's Disease: Epidemiology, Clinical Manifestations, and Diagnosis[J]. Expert Rev Clin Immunol, 2017, 13(1): 57-65.
|
| [3] |
Diedrichs MM, Kaufmann U, Wildner G. The immunopathogenesis of chronic and relapsing autoimmune uveitis Lessons from experimental rat[J]. Prog Retin Eye Res, 2018 , 65：107-126.
|
| [4] |
O'Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity[J]. Nat Rev Immunol.2002, 2(1): 37-45.
|
| [5] |
Kenji N, Kazuichi M, Kazuko U, et al. Simultaneous Analysis of Multiple Cytokines in the Vitreous of Patients with Sarcoid Uveitis[J]. Investigative Opthalmology & Visual Science, 2012, 53(7): 3827-3833.
|
| [6] |
Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFα regulation in uveitis: focus on RNA-binding proteins[J]. Prog Retin Eye Res, 2010, 29(6): 610-621.
|
| [7] |
Nourshargh S, Alon R. Leukocyte migration into inflamed tissues[J]. Immunity.2014, 41(5): 694-707.
|
| [8] |
Bharadwaj AS, Schewitz-Bowers LP, Wei L, et al. Intercellular adhesion molecule 1 mediates migration of Th1 and Th17 cells across human retinal vascular endothelium[J]. Invest Ophthalmol Vis Sci, 2013, 54(10): 6917-6925.
|
| [9] |
Ashander LM, Binoy A, Ma Y, et al. Targeting Endothelial Adhesion Molecule Transcription for Treatment of Inflammatory Disease: A Proof-of-Concept Study[J]. Mediators of Inflammation, 2016: 1-8.
|
| [10] |
Saishin Y, Saishin Y, Takahashi K, et al. Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier[J]. Journal of Cellular Physiology, 2003, 195(2): 210-219.
|
| [11] |
Nishikiori N, Osanai M, Chiba H, et al. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy[J]. Diabetes, 2007, 56(5): 1333-1340.
|
| [12] |
Luna JD, Chan CC, Derevjanik NL, et al. Blood-retinal barrier (BRB) breakdown in experimental autoimmune uveoretinitis: comparison with vascular endothelial growth factor, tumor necrosis factor alpha, and interleukin-1beta-mediated breakdown[J]. Neurosci Res, 1997, 49(3): 268-280.
|
| [13] |
Aveleira Célia A, Lin CM, Abcouwer Steven F, et al. TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability[J]. Diabetes, 2010, 59: 2872-2882.
|
| [14] |
Caspi RR. A look at autoimmunity and inflammation in the eye[J]. Clin Invest, 2010, 120(9): 3073-3083.
|
| [15] |
Nadkarni, Mauri S, Ehrenstein C, et al. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta[J]. Journal of Experimental Medicine, 2007, 204(1): 33.
|
| [16] |
Yang P, Ji L, Zhou H, et al. Disturbed expression of Fas/FasL on CD4(+) and CD8(+)T cells in Behcet's disease, Vogt-Koyanagi-Harada syndrome, and idiopathic anterior uveitis[J]. Ocul Immunol Inflamm, 2001, 9(3): 185-191.
|
| [17] |
Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel[J]. Am J Ophthalmol, 2000, 130(4): 492-513.
|
| [18] |
Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial[J]. Lancet, 2009, 374 (9685): 210-221.
|
| [19] |
Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients[J]. Autoimmun, 2015, 62: 67-74.
|
| [20] |
Touhami S, Diwo E, Sève P, et al. Expert opinion on the use of biological therapy in non-infectious uveitis[J]. Expert Opin Biol Ther, 2019, 19(5): 477-490.
|
| [21] |
Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis[J]. Arthritis Care Res (Hoboken), 2019, 71(6): 703-716.
|
| [22] |
Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients[J]. Clin Rheumatol, 2019, 38(2): 407-415.
|
| [23] |
Santos-Gómez M, Calvo-Río V, Blanco R, et al. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study[J]. Clin Exp Rheumatol, 2016, 34(6): 34-40.
|
| [24] |
Hu Y, Huang Z, Yang S, et al. Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-Analysis[J]. Front Pharmacol, 2020, 11: 941.
|
| [25] |
Lamattina KC, Goldstein DA. Adalimumab for the treatment of uveitis[J]. Expert Rev Clin Immunol, 2017, 13(3): 181.
|
| [26] |
Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study[J]. Ocul Pharmacol Ther, 2008, 24(3): 351-361.
|
| [27] |
La TF, Cattalini M, Teruzzi B, et al. Efficacy of adalimumab in young children with juvenile idiopathic arthritis and chronic uveitis: a case series s[J]. BMC Research Notes, 2014, 7(1): 316.
|
| [28] |
Mccracken C, Yeh S, Jenkins K, et al. Timing of infliximab and adalimumab initiation despite methotrexate in children with chronic non-infectious anterior uveitis[J]. Eye, 2019, 33(4): 629-639.
|
| [29] |
Halilbasic M, Vodencarevic AN, Cosickic A, et al. Adalimumab in Treatment of Uveitis in Pediatric Behcet's Disease-a Case Report[J]. Mater Sociomed, 2021, 33(1): 78-81.
|
| [30] |
Bawazeer A, Raffa LH. Clinical experience with adalimumab in the treatment of ocular Behet disease[J]. Ocular Immunology & Inflammation, 2010, 18(3): 226-232.
|
| [31] |
Fatima J, Amanda S. A rare case of suicidal ideation related to Adalimumab use[J]. Open Access Rheumatol, 2018, 17, (10): 113-115.
|
| [32] |
Mendes D, Alves C, Bate MF. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events[J]. Clinical Pharmacy & Therapeutics, 2014, 39(3): 307-313.
|
| [33] |
Jaffe GJ, Dick AD, Brézin A, et al. Adalimumab in Patients with Active Noninfectious Uveitis[J]. New England Journal of Medicine, 2016, 375(10): 932-943.
|
| [34] |
Fabiani C, Vitale A, Rigante D, et al. Predictors of sustained clinical response in patients with Behet's disease-related uveitis treated with infliximab and adalimumab[J]. Clinical Rheumatology, 2018, 37(6): 1715-1720.
|
| [35] |
白琳，杨培增. 白塞病葡萄膜炎的治疗与展望[J]. 中华实验眼科杂志，2016，34(8)：761-764.
|
| [36] |
Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behçet's disease[J]. Lancet, 2001, 358(9278): 295-296.
|
| [37] |
孙妍，任立敏. IFX治疗难治性贝赫切特综合征眼炎1例并文献复习[J]. 中华临床免疫和变态反应杂志，2021，6(4)：4.
|
| [38] |
袁艺，史婧，刘金晶，等. 英夫利西单抗治疗难治性白塞病葡萄膜炎的疗效及安全性[J]. 中华临床免疫和变态反应杂志，2019，13(1)：62-67.
|
| [39] |
Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, et al. Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients[J]. J Rheumatol, 2021, 48(5): 741-750.
|
| [40] |
Posarelli C, Arapi I, Figus M, et al. Biologic agents in inflammatory eye disease[J]. Journal of Ophthalmic & Vision Research, 2011, 6(4): 309-316.
|
| [41] |
Refaat M, Abdullatif AM, Hamza MM, et al. Monthly intravitreal infliximab in behçet's disease active posterior uveitis: A Long-Term Safety Study[J]. Retina, 2021, 41(8): 1739-1747.
|
| [42] |
张美芬，赵潺，温鑫，等. 依那西普治疗复发性白塞病葡萄膜炎的短期疗效和安全性研究[J]. 中华眼科杂志，2010，46(2)：6.
|
| [43] |
Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients[J]. Semin Arthritis Rheum, 2016, 46(1): 95-101.
|
| [44] |
Fabiani C, Sota J, Rigante D, et al. Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet[J]. Ocul Immunol Inflamm, 2019, 27(1): 58-63.
|
| [45] |
Palmou-Fontana N, Calvo-Río V, Martín-Varillas JL, et al. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review[J]. Clin Exp Rheumatol, 2018, 36(4): 652-657.
|
| [46] |
Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome[J]. Annals of the Rheumatic Diseases, 2018, 77(6): 808-818.
|
| [47] |
Hwang DK, Hwang YS, Tsai ML, et al. Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan[J]. Taiwan J Ophthalmol, 2018, 8(3): 117-120.
|
| [48] |
Dick AD, Rosenbaum JT, Al-Dhibi HA, et al. Fundamentals of Care for Uveitis International Consensus Group. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative[J]. Ophthalmology, 2018, 125(5): 757-773.
|
| [49] |
Keino H, Okada AA, Watanabe T, et al. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study[J]. Ocular Immunology & Inflammation, 2016, 25(1): 46-51.
|
| [50] |
Hiyama T, Harada Y, Doi T, et al. Early administration of adalimumab for paediatric uveitis due to Behçet's disease[J]. Pediatric Rheumatology, 2019，17(1) : 29.
|
| [51] |
Hamam RN, Barikian AW, Antonios RS, et al.Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study[J]. Ocul Immunol Inflamm, 2016, 24(3): 319-326.
|
| [52] |
Kunimi K, Usui Y, Asakage M, et al. Anti-TNF-α Therapy for Refractory Uveitis Associated with Behçet's Syndrome and Sarcoidosis: A Single Center Study of 131 Patients[J]. Ocul Immunol Inflamm, 2020: 1-8.
|
| [53] |
Fabiani C, Sota J, Rigante D, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies[J]. Clin Rheumatol, 2018, 37(10): 2805-2809.
|
| [54] |
Ohno S, Umebayashi I, Matsukawa M, et al. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan[J]. Arthritis Res Ther, 2019, 21(1): 2.
|